Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Faris

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Oncology Research and Treatment|September 13, 2021
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse EventsPatrick Schöffski, Nicole Concin, Cristina Suarez, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
American Journal of Clinical Oncology|January 31, 2017
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic CancerJennifer Y Wo, Andrzej Niemierko, David P Ryan, et al.
Cancer|February 7, 2014
Mutational analysis and clinical correlation of metastatic colorectal cancerAndrea L Russo, Darrell R Borger, Jackie Szymonifka, et al.
JAMA Oncology|May 26, 2018
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.
The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.
The Oncologist|May 10, 2013
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experienceJason E Faris, Lawrence S Blaszkowsky, Shaunagh McDermott, et al.
Cancer Discovery|April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal CancerRobin M J M van Geel, Josep Tabernero, Elena Elez, et al.
The Oncologist|August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric CancersSurendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Oncology Research and Treatment|September 13, 2021
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse EventsPatrick Schöffski, Nicole Concin, Cristina Suarez, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
American Journal of Clinical Oncology|January 31, 2017
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic CancerJennifer Y Wo, Andrzej Niemierko, David P Ryan, et al.
Cancer|February 7, 2014
Mutational analysis and clinical correlation of metastatic colorectal cancerAndrea L Russo, Darrell R Borger, Jackie Szymonifka, et al.
JAMA Oncology|May 26, 2018
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.
The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.
The Oncologist|May 10, 2013
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experienceJason E Faris, Lawrence S Blaszkowsky, Shaunagh McDermott, et al.
Cancer Discovery|April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal CancerRobin M J M van Geel, Josep Tabernero, Elena Elez, et al.
The Oncologist|August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric CancersSurendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
Pageof 4